Optogenetics explained: the light switch for nerve cells that won the 2026 Nobel Prize in medicine

On Monday, October 5, the Nobel Assembly at Karolinska Institutet in Stockholm awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion channels and optogenetics”. The laureates are Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg.

The word in that citation is unfamiliar outside laboratories, yet the method it names has been used in thousands of brain studies. This explainer covers what optogenetics is, where it came from, what it has revealed, and how far it is from being a medical treatment.

What optogenetics is

Optogenetics is a way of controlling living cells with light. Nerve cells do not normally respond to light. The method gives a chosen group of them a gene borrowed from a microbe, and the gene instructs the cell to build a light-sensitive protein in its outer membrane. From then on, a pulse of light on those cells changes their electrical activity.

A methods primer written by an international group of specialists puts it this way: cells that are naturally light-insensitive can be made photosensitive and addressable by illumination. The technique works by using a combination of genetic engineering and light.

The proteins involved are ion channels and pumps. An ion channel is a pore in a cell’s membrane that lets electrically charged particles, called ions, pass through. A nerve cell fires when enough positive ions rush in. A light-gated channel is one that opens when light strikes it, so light becomes the trigger.

Two things set the method apart from older tools such as electrodes and drugs. The first is selectivity, since only the cells carrying the added gene respond, even when they are tangled among millions of others. The second is speed, since a pulse of light acts within thousandths of a second. Deisseroth described the wider shift to the news site STAT after the announcement. “When you think about light in science or light in medicine, you think of it as an observational tool. It’s a way to collect information. But with optogenetics, it’s the complete opposite of that,” he said.

How optogenetics grew out of a single-celled alga

The story starts with a question about a microscopic plant. According to STAT, the work started in the early 1990s at the Max Planck Institute, when Hegemann wondered how a single-cell green alga called Chlamydomonas could swim toward light.

The answer was a protein. In the Nobel Assembly’s summary, Peter Hegemann and Georg Nagel discovered a remarkable protein, channelrhodopsin, in a single-celled alga. When it is illuminated by blue light, a channel opens through the protein. Charged ions then flow into the cell, creating an electrical impulse.

Their key paper appeared in 2003. It showed that the protein, taken from the green alga Chlamydomonas reinhardtii and placed in frog eggs and mammalian cells, still worked. In the authors’ words it is a directly light-switched cation-selective ion channel, a cation being a positively charged ion. The paper closed with a sentence that pointed to everything that followed, noting that the protein may be used to depolarize small or large cells, simply by illumination. To depolarize a nerve cell is to push it toward firing.

Deisseroth’s laboratory took that step with neurons. A 2005 paper, with graduate student Edward Boyden as first author and Nagel among the co-authors, described putting the algal gene into nerve cells with an engineered virus. The opening line set out the ambition: “Temporally precise, noninvasive control of activity in well-defined neuronal populations is a long-sought goal of systems neuroscience.” The team reported reliable, millisecond-timescale control of neuronal spiking, the firing of nerve cells.

Two years later Deisseroth made this light-controlled switch for nerve cells work in the brains of living mice, the Nobel Assembly notes. In the same year the Stanford group added an off switch. They adapted a second microbial protein, an archaeal light-driven chloride pump, for temporally precise optical inhibition of neural activity. Archaea are single-celled microbes, and inhibition here means silencing a nerve cell at a chosen instant. Because the two proteins respond to different colors of light, the same cells could be activated with one color and silenced with another.

Who is credited with optogenetics

Nobel Prizes go to at most three people, and the choice has drawn comment. STAT reported that on social media many noted the omission of Ed Boyden, who was the first author on Deisseroth’s landmark 2005 paper and a Ph.D. student in his lab.

The committee’s own background material named others. Among them were Gero Miesenböck, who achieved the first genetic sensitization to light of nonphotoreceptive neurons in 2002, meaning nerve cells that do not normally respond to light, and Zhuo-Hua Pan, a vision scientist at Wayne State University. Pan, who in 2004 successfully tried channelrhodopsin in ganglion cells of the eye, did not see the paper published until 2006. The committee chair declined to comment on the reasons behind selecting the winners.

What optogenetics has shown about the brain

Before the method existed, brain science could mostly observe. Researchers could record that certain cells were active during a behavior, or note what was lost when an area was damaged. In the Nobel Assembly’s account of 20th-century researchers, the methods used meant they could not prove causal relationships.

Optogenetics made the causal experiment possible: switch on one cell type, and see what the animal does.

An early demonstration concerned sleep. A small cluster of cells deep in the brain produces a chemical messenger called hypocretin, and loss of its function has been linked to narcolepsy. What nobody knew, the researchers wrote in 2007, was whether activity in those cells is sufficient to drive awakening from sleep states or is simply correlated with it. They placed channelrhodopsin in the cells of freely moving mice and delivered light through a thin optical cable. Stimulation increased the probability of transition to wakefulness from either slow wave sleep or rapid eye movement sleep, the two main sleep states. The cells were a cause of waking and not a bystander.

A second example bears on an existing treatment. Deep brain stimulation (DBS) is a therapeutic option for intractable neurological and psychiatric disorders, including Parkinson’s disease and major depression. Surgeons implant an electrode and pass current through it, and it helps many patients, yet because brain tissue around the electrode contains many cell types it has been challenging to elucidate the relevant target cell types or underlying mechanisms. Working in freely moving parkinsonian rodents, animals with a Parkinson’s-like condition, the Stanford team switched each part of the circuit on and off in turn. The benefit, they reported, could be accounted for by stimulating nerve fibers that project into the target region from elsewhere.

The method was slow to catch on. In a 2015 retrospective Deisseroth wrote that for roughly its first five years “there were difficulties in implementation, few publications and limited biological findings”. The following years brought, by his count, the publication of thousands of discoveries and insights into the function of nervous systems and beyond.

Its reach now extends past the brain. The primer’s authors say the approach is primed to have a similar impact in other fields, including cardiology, cell biology and plant sciences.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” said Per Svenningsson, who chairs the Nobel Committee for Physiology or Medicine.

Optogenetics as a treatment: one blind patient

The first use in a person came through the eye. Retinitis pigmentosa is a neurodegenerative eye disease where loss of photoreceptors can lead to complete blindness. Photoreceptors are the rods and cones, the light-detecting cells at the back of the eye. In this disease they die, while the nerve cells that normally carry their signals to the brain, called retinal ganglion cells, often survive.

The idea of turning those surviving cells into light detectors dates to animal work. In 2006 Pan’s group showed that channelrhodopsin delivered to the inner retina of mice with photoreceptor degeneration can restore the ability of the retina to encode light signals and transmit the light signals to the visual cortex.

Fifteen years later a team led by José-Alain Sahel of Sorbonne Université in Paris and the University of Pittsburgh, with Botond Roska in Basel, reported a human case in Nature Medicine. A blind patient received an injection into one eye of a virus carrying the gene for a light-sensitive protein. The treatment had a second part, a pair of engineered goggles. The goggles detect local changes in light intensity and project corresponding light pulses onto the retina in real time.

The result was modest and real. The patient perceived, located, counted and touched different objects using the vector-treated eye alone while wearing the goggles. The vector-treated eye means the one that received the injection. Recordings from the scalp picked up matching activity over the visual part of the brain. Control conditions showed what was responsible: the patient could not visually detect any objects before injection with or without the goggles or after injection without the goggles.

The authors chose their words carefully. They called it the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy. One attraction of the approach is that it is mutation-independent, meaning it does not depend on which of the many faulty genes caused a person’s blindness.

Work has continued since. In ongoing clinical trials, scientists have been working to restore vision in people who have become blind due to retinitis pigmentosa, the BBC reported, citing the Nobel committee. The committee’s own phrasing was that researchers are using the method in attempts to restore sight in people with visual impairment.

Why optogenetics is hard to use in people

The eye is a natural first target. Light reaches the retina from outside, and a gene can be injected directly into it.

The brain offers neither advantage. Every optogenetic experiment has two requirements, a gene delivered into the right cells and light delivered to the same spot. In the mouse sleep study, the light arrived through an optical cable placed deep in the brain. Delivering a gene and a light source to the same spot inside a human skull would mean surgery.

That gap explains the committee’s choice of words. Researchers have taken “the first steps” towards using optogenetics as a medical treatment, the BBC quoted it as saying. The prize recognizes a research tool. What that tool has taught about circuits may guide therapies that use other means, such as better-aimed electrical stimulation, and the Parkinson’s study is an example of that route.

Limits of the evidence on optogenetics

Nearly everything described here comes from mice, rats and cells in dishes. Circuits identified in a mouse do not always work the same way in a human brain.

The human evidence described here is one person. The patient’s vision was limited to locating and counting objects under test conditions, with the goggles on. The report does not establish how long the effect lasts, how many patients would respond, or whether sight could improve with training.

The historical record carries its own caveat. Deisseroth’s 2015 account is a participant’s history, and the dispute over credit shows that others tell it differently.

Optogenetics has turned observation of the brain into experiment in animals over two decades, and its first published result in human medicine was partial sight in a single blind patient.